The MIST Phase 2 clinical trial, supporting the potential of hematopoietic (blood cell-producing) stem cell transplant (HSCT) to significantly slow disability progression in highly active relapsing-remitting multiple sclerosis (RRMS) patients, has received a Distinguished Clinical Research Achievement Award from the Clinical Research (CR) Forum.
Five years after the transplant, most treated patients showed no further disease progression or activity, a press release announcing the honor stated.
The CR Forum is a nonprofit association of clinical research experts and leaders at leading academic health centers in the U.S. Each year, it recognizes exceptional studies through its Top 10 Clinical Research Achievement Awards.
Two of these awards are considered Distinguished Clinical Research Achievement Awards, and highlight clinical studies whose creativity, innovation, and novelty carry great promise for patients. Each carries a cash prize of $5,000.
His project is titled “Hematopoietic Stem Cell Transplantation for Frequently Relapsing Multiple Sclerosis.”
HSCT is an intensive therapy that rebuilds a patient’s immune system. The first step is to collect a patient’s own (meaning, autologous) healthy hematopoietic stem cells from the bone marrow, followed by a fairly non-aggressive combination of chemotherapy (non-myeloablative) that kills the rest of the patient’s immune cells.
The hematopoietic stem cells are then infused back to the patient to generate a new, and healthy immune system.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?